Search for drugs:
Typing the drug name to query
DALFAMPRIDINE
DIR Classification
Classification:Ambiguous
Severity Score:1.0
Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF
- CLINICAL PHARMACOLOGY
- Pharmacodynamics
- Dalfampridine does not prolong the QTc interval and does not have a clinically important effect on QRS duration.
Postmarketing Surveillance
Contingency Table:
Current Drug
Other Drugs
QT Prolongation
6
24086
Other ADRs
156648
38224939
Odds Ratio = 0.061
Drug Property Information
ATC Code(s):
Active Ingredient:DALFAMPRIDINE
Active Ingredient UNII:BH3B64OKL9
Drugbank ID:DB06637
PubChem Compound:1727
CTD ID:D015761
PharmGKB:PA166123389
CAS Number:504-24-5
Dosage Form(s):tablet, extended release
Route(s) Of Administrator:oral
Daily Dose:
Chemical Structure: 
SMILE Code:
NC1=CC=NC=C1
NC1=CC=NC=C1
Reference
1: The safety profile of dalfampridine extended release in multiple sclerosis clinical trials.
[Cornblath David R,Bienen E Jay,Blight Andrew R]Clin Ther,2012 May;34(5):1056-69. PMID: 22497693
Disclaimer:
The content of this database of QT prolongation is intended for educational and scientific research purposes only. It is not intended as a substitute for professional medical advice, diagnosis or treatment.
Any mention of commercial products is for clarification and not intended as endorsement.